[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 26, 1953


Author Affiliations

Ohio; Cleveland
From the Department of Dermatology and Syphilology, University Hospitals, and the School of Medicine, Western Reserve University.

JAMA. 1953;153(17):1515-1516. doi:10.1001/jama.1953.02940340017006

The article by Page1 on the treatment of 18 patients with lupus erythematosus with quinacrine hydrochloride (Atabrine) has initiated widespread interest in the United States regarding this subject. As early as 1940, Prokoptchouk2 reported the use of quinacrine (Acrichin) in 35 patients with lupus erythematosus and was impressed with its effectiveness. Popoff and Kutinscheff3 observed remission of lupus erythematosus in six patients treated with quinacrine in 1941. Krynski4 treated six patients during the period 1940-1945. Pseudoicterus developed in one patient, and another showed a temporary psychic disturbance. He concluded that the method was effective but that the high incidence of side-reactions probably made its more general usage unwarranted. It has since been shown that the American product Atabrine (quinacrine hydrochloride, U. S. P.) probably is less toxic and produces fewer side-effects than Acrichin the Russian product or its German analogue Atabrin.5 Bispham,6 in a

First Page Preview View Large
First page PDF preview
First page PDF preview